SELECTA BIOSCIENCES, INC. Patent applications |
Patent application number | Title | Published |
20160128987 | METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS WITH RAPAMYCIN IN A STABLE, SUPER-SATURATED STATE - Disclosed are compositions and methods that provide synthetic nanocarriers that comprise hydrophobic polyester carrier material and rapamycin that is in a stable, super-saturated amount. In some embodiments, the synthetic nanocarriers are also initially sterile filterable. In other embodiments, the rapamycin is present in the synthetic nanocarrier compositions in an amount that is less than 50 weight % rapamycin/hydrophobic polyester carrier material in the composition. | 05-12-2016 |
20160128986 | METHODS AND COMPOSITIONS RELATED TO THE USE OF LOW HLB SURFACTANTS IN THE PRODUCTION OF SYNTHETIC NANOCARRIERS COMPRISING A RAPALOG - Disclosed are compositions and methods related to synthetic nanocarriers comprising a hydrophobic carrier material, a rapalog, and a non-ionic surfactant with a hydrophilic-lipophilic balance (HLB) value less than or equal to 10. | 05-12-2016 |
20160074532 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE EDITING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-17-2016 |
20160074531 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE THERAPY ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-17-2016 |
20160074427 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE EXPRESSION MODULATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-17-2016 |
20160074372 | METHODS AND COMPOSITIONS FOR ATTENUATING EXON SKIPPING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-17-2016 |
20160067228 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-10-2016 |
20160030555 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells. | 02-04-2016 |
20160030554 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY - Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen. | 02-04-2016 |
20160022650 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes. | 01-28-2016 |
20150374815 | METHODS AND COMPOSITIONS FOR TREATMENT WITH SYNTHETIC NANOCARRIERS AND IMMUNE CHECKPOINT INHIBITORS - Disclosed are synthetic nanocarrier compositions and immune checkpoint inhibitor compositions and related methods for administration to a subject. | 12-31-2015 |
20150335762 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS - Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins. | 11-26-2015 |
20150328333 | TOLEROGENIC SYNTHETIC NANOCARRIERS - This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses. | 11-19-2015 |
20150328309 | DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods. | 11-19-2015 |
20150328300 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS - This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner. | 11-19-2015 |
20150320884 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion). | 11-12-2015 |
20150320870 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR INDUCING REGULATORY B CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells. | 11-12-2015 |
20150320856 | CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments. | 11-12-2015 |
20150320728 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+T cell help specific to an antigen. | 11-12-2015 |
20140356361 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS - This invention relates to repeated administration of antigen-specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the protocol has been previously shown not to induce immunosuppression in a subject. | 12-04-2014 |
20140335186 | METHODS AND COMPOSITIONS FOR ENHANCING CD4+ REGULATORY T CELLS - Disclosed are methods and related compositions for administering immunosuppressants and therapeutic macromolecules for enhancing CD4+ regulatory T cells. | 11-13-2014 |
20140328924 | DELIVERY OF IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE-LIFE AND ANTIGEN FOR THE INDUCTION OF IMMUNE TOLERANCE - This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule. | 11-06-2014 |
20140328923 | DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES - Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses. | 11-06-2014 |
20140328922 | LOCAL, CONCOMITANT ADMINISTRATION OF TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE TYPE I AND TYPE IV HYPERSENSITIVITY - Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity. | 11-06-2014 |
20140328921 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN - This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions. | 11-06-2014 |
20140328854 | TOLEROGENIC SYNTHETIC NANOCARRIERS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR ENHANCED PHARMACODYNAMIC EFFECTS - Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions. | 11-06-2014 |
20140242173 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS - This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that encapsulate labile immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. | 08-28-2014 |
20140199340 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR INDUCING REGULATORY B CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells. | 07-17-2014 |
20140193453 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS - This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner. | 07-10-2014 |
20140030344 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOSTIMULATORY AGENTS - This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that encapsulate labile immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. | 01-30-2014 |
20130059009 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that are produced from combining itDCs with antigen in particulate form, as well as related compositions and methods. | 03-07-2013 |
20130058978 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR INDUCING REGULATORY B CELLS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate regulatory B cells, as well as related compositions and methods. | 03-07-2013 |
20130058977 | COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DENDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES - Disclosed are induced tolerogenic dendritic cells (itDCs) produced by combining itDCs with externally loadable MHC Class I-restricted epitopes, as well as related compositions and methods. | 03-07-2013 |
20130058976 | ALLERGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS FOR ALLERGY THERAPY - Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
20130058975 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing undesired humoral immune responses, as well as related compositions and methods. | 03-07-2013 |
20130058974 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing CD8+ T cell immune responses, as well as related compositions and methods. | 03-07-2013 |
20130058970 | INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES - Disclosed are induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods, for reducing systemic inflammatory cytokines. | 03-07-2013 |
20130058963 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate CD8+ regulatory T cells, as well as related compositions and methods. | 03-07-2013 |
20130058902 | DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS - Disclosed are induced tolerogenic dendritic cells (itDCs) produced from dendritic cell subsets that possess a desired physiological characteristic, as well as related compositions and methods. | 03-07-2013 |
20130058901 | TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
20130058894 | THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are therapeutic protein-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
20130039954 | CONTROL OF ANTIBODY RESPONSES TO SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions that comprise B cell antigen for desired antibody production and an off-target response attenuating polymeric coating as well as related methods. | 02-14-2013 |
20130028941 | SYNTHETIC NANOCARRIERS THAT GENERATE HUMORAL AND CYTOTOXIC T LYMPHOCYTE (CTL) IMMUNE RESPONSES - Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions. | 01-31-2013 |
20130028857 | SYNTHETIC NANOCARRIERS COMPRISING POLYMERS COMPRISING MULTIPLE IMMUNOMODULATORY AGENTS - This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise polymers that comprise at least two immunomodulatory agent moieties. | 01-31-2013 |
20120301510 | TOLEROGENIC SYNTHETIC NANOCARRIERS COUPLED TO CD1D-RESTRICTED ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising CD1d-restricted antigens and immunosuppressants that provide tolerogenic immune responses. | 11-29-2012 |
20120301498 | CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments. | 11-29-2012 |
20120294888 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY - Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen. | 11-22-2012 |
20120276160 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR REGULATING INNATE IMMUNE RESPONSES - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to reduce antigen-specific activation of innate immune cells. | 11-01-2012 |
20120276159 | TOLEROGENIC SYNTHETIC NANOCARRIERS - This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses. | 11-01-2012 |
20120276158 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes. | 11-01-2012 |
20120276157 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen. | 11-01-2012 |
20120276156 | TOLEROGENIC SYNTHETIC NANOCARRIER COMPOSITIONS WITH TRANSPLANTABLE GRAFT ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens. | 11-01-2012 |
20120276155 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells. | 11-01-2012 |
20120276134 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion). | 11-01-2012 |
20120276133 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR INDUCING REGULATORY B CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells. | 11-01-2012 |
20120276109 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS - Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins. | 11-01-2012 |
20120244222 | OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS - This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use. | 09-27-2012 |
20120177701 | COMPOSITIONS COMPRISING IMMUNOSTIMULATORY NUCLEIC ACIDS AND RELATED METHODS - Immunostimulatory compositions include an isolated nucleic acid molecule that includes one or more nucleotide sequences from 5′- or 3′-terminal regions of positive-sense, single-stranded RNA virus genomes and/or or nucleotide sequences from a 5′-terminal regions of negative-sense, single-stranded RNA virus genomes. | 07-12-2012 |
20120171229 | SYNTHETIC NANOCARRIERS WITH REACTIVE GROUPS THAT RELEASE BIOLOGICALLY ACTIVE AGENTS - This invention relates to compositions, and related compounds and methods, of conjugates of synthetic nanocarriers, or components thereof, and biologically active agents, such as immunomodulatory agents, antigens, anticancer agents or antiviral agents. The biologically active agents are released from the synthetic nanocarriers in the presence of a reducing agent or by reaction with a thiol. | 07-05-2012 |
20120114677 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS - Provided herein are compounds and related composition and methods that may be used to raise an antibody response to nicotinic compounds, in some embodiments. | 05-10-2012 |
20120070493 | TARGETED MULTI-EPITOPE DOSAGE FORMS FOR INDUCTION OF AN IMMUNE RESPONSE TO ANTIGENS - Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed. | 03-22-2012 |
20120064110 | SYNTHETIC NANOCARRIER VACCINES COMPRISING PEPTIDES OBTAINED OR DERIVED FROM HUMAN INFLUENZA A VIRUS HEMAGGLUTININ - This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus hemagglutinin. | 03-15-2012 |
20120058154 | SYNTHETIC NANOCARRIER VACCINES COMPRISING PEPTIDES OBTAINED OR DERIVED FROM HUMAN INFLUENZA A VIRUS M2E - This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus M2 protein. | 03-08-2012 |
20120058153 | SYNTHETIC NANOCARRIER VACCINES COMPRISING PROTEINS OBTAINED OR DERIVED FROM HUMAN INFLUENZA A VIRUS HEMAGGLUTININ - This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include polypeptides obtained or derived from human influenza A virus hemagglutinin. | 03-08-2012 |
20120027806 | DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods. | 02-02-2012 |
20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES - Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient. | 12-01-2011 |
20110293701 | MULTIVALENT SYNTHETIC NANOCARRIER VACCINES - The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods. | 12-01-2011 |
20110293700 | NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT - Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods. | 12-01-2011 |
20110272836 | ECCENTRIC VESSELS - Vessels, including non-symmetric vessels for mixing fluids, are disclosed. In one aspect, the vessel is one that has a non-rotationally-symmetric interior surface. For example, the vessel may have an oblique frustoconical shape. At least a portion of the mixing vessel may have horizontal cross-sections having varying area, in some embodiments. The vessel may be formed from any suitable material, e.g., glass, plastic, or stainless steel. Such vessels may be used, according to certain embodiments, to create single, double or other multiple emulsions, for example, by exposing liquids or fluids contained therein to relatively high shear rates. In some cases, the vessel may be designed to be pharmaceutical-grade and/or meet ASME Bioprocessing Equipment (ASME-BPE) standards. For instance, the vessel may be used under conditions where the vessel is sterile, and/or the vessel may have a polished internal surface. In some cases, the vessel includes a temperature control system surrounding at least a portion of the vessel. Other aspects relate to methods of using such vessels, methods of creating or preparing such vessels, or kits involving such vessels. | 11-10-2011 |
20110262491 | EMULSIONS AND METHODS OF MAKING NANOCARRIERS - This invention relates, in part, to methods of using emulsions for making synthetic nanocarriers and the synthetic nanocarriers formed by such methods. | 10-27-2011 |
20110223201 | Immunonanotherapeutics Providing a Th1-Biased Response - Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable. | 09-15-2011 |
20110171248 | SYNTHETIC VIRUS-LIKE PARTICLES CONJUGATED TO HUMAN PAPILLOMAVIRUS CAPSID PEPTIDES FOR USE AS VACCINES - Disclosed are compositions and related methods that involve a synthetic nanocarrier that includes at least one peptide obtained from Human papillomavirus L1 or L2 capsid protein; wherein the peptide is coupled to an external surface of the synthetic nanocarrier. | 07-14-2011 |
20110110965 | COMPOSITIONS THAT INDUCE T CELL HELP - The present invention relates, at least in part, to compositions, and related methods, comprising MHC II binding peptides. In one embodiment, the MHC II binding peptides comprise a peptide having at least 70% identity to a natural HLA-DP binding peptide, HLA-DQ binding peptide, or HLA-DR binding peptide. | 05-12-2011 |
20110027217 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS - This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner. | 02-03-2011 |
20110020388 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS - This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that encapsulate labile immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. | 01-27-2011 |
20100303850 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE - This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers. | 12-02-2010 |